Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of...

* Reuters is not responsible for the content in this press release.

Tue Apr 7, 2009 8:01am EDT 

Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies
of AVN-101, Potent Small Molecule for Treatment of Alzheimer's Disease.

SAN DIEGO, April 7 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced
today an initiation of Phase I clinical studies of AVN-101, a potent small
molecule for treatment of Alzheimer's disease. The results of Phase I studies
are expected to be available in May 2009. Based on these and other results,
Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into Phase II clinical
trials in Q2 2009. Avineuro Pharmaceuticals, Inc. presented at the 9th
International Conference - AD/PD 2009 - Prague, Czech Republic, March 11-15,
2009.
 
About Avineuro Pharmaceuticals, Inc.: 
Avineuro discovers and develops novel small molecules for unmet medical needs
in neurology and psychiatry. Avineuro emphasizes a rational approach to drug
discovery that combines modern medicinal chemistry with streamlined
pre-clinical and clinical development studies, thus allowing a fast transition
to proof-of-concept product candidates.
 

 
SOURCE  Avineuro Pharmaceuticals, Inc.

Yan Lavrovsky, CEO, Avineuro Pharmaceuticals, Inc., +1-858-436-1537, fax,
+1-858-228-9798, ylavrovsky@avineuro.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.